Yaz Lawyers And Judges Establish Yaz Trial Schedule
Yaz lawyers and leading judges in Yaz and Yasmin litigation convened in Philadelphia last Wednesday, May 18, 2011 to establish a trial schedule for the first several of more than 7,000 Yaz and Yasmin lawsuits filed in US courts.
First Yaz pulmonary embolism bellwether trial scheduled
According to materials released from the status conference, the first bellwether trial in Yaz litigation is tentatively set for January 12, 2012. The first trial will involve a Yaz pulmonary embolism case consolidated in the federal Yaz MDL. Two state pulmonary embolism trials will quickly follow the MDL trial.
Yaz gallbladder disease MDL bellwether trials scheduled
In April 2012, the first Yaz MDL gallbladder disease bellwether trial is set to commence. Two state gallbladder disease trials will ensue within two months.
Yaz deep vein thrombosis (DVT) trial scheduled
Finally, in late June 2012, a bellwether trial is set to commence involving a Yaz MDL venous thromboembolism case, often referred to as a deep vein thrombosis or DVT. Two state venous thromboembolism cases will follow within two months.
In all, nine Yaz trials are set to commence within nine months, a rigorous trial schedule that will carry significant implications for thousands of women who are engaged in Yaz litigation.
Federal Yaz lawsuits presided over by Judge Herndon
Chief Judge David R. Herndon of the Southern District of Illinois, presided over last Wednesday’s Yasmin lawsuit update status conference. Judge Herndon is overseeing thousands of federal Yaz lawsuits consolidated in his district. There are also hundreds of state Yaz lawsuits consolidated in New Jersey and Pennsylvania.
The first Yaz bellwether trial was originally set to commence on September 12, 2011. It was ordered delayed in April after Yaz lawyers on both sides of the litigation requested more time for expert testimony and evidence discovery.
According to minutes released from the status conference, Judge Herndon said, “something drastic would have to happen” to delay the Yaz trial schedule established at the conference.
The new trial schedule comes a month after a flurry of studies were published in prominent scientific journals showing Yaz side effects to be occurring in higher rates than of other oral contraceptives. Bayer, which owns the patents on Yaz and Yasmin, has discounted the studies as clinically insignificant.
Yaz lawyers are currently evaluating hundreds of additional claims that have not yet joined the ongoing litigation.